NZ335835A - Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients - Google Patents
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patientsInfo
- Publication number
- NZ335835A NZ335835A NZ335835A NZ33583599A NZ335835A NZ 335835 A NZ335835 A NZ 335835A NZ 335835 A NZ335835 A NZ 335835A NZ 33583599 A NZ33583599 A NZ 33583599A NZ 335835 A NZ335835 A NZ 335835A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mbp
- myelin basic
- basic protein
- residues
- administration
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 title 1
- 102000047918 Myelin Basic Human genes 0.000 title 1
- 101710107068 Myelin basic protein Proteins 0.000 title 1
- 230000002502 anti-myelin effect Effects 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 5
- 102000054064 human MBP Human genes 0.000 abstract 5
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 230000002411 adverse Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 238000007913 intrathecal administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/327,357 US5817629A (en) | 1991-10-22 | 1994-10-21 | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| NZ29391099 | 1999-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ335835A true NZ335835A (en) | 2000-11-24 |
Family
ID=26651641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ335835A NZ335835A (en) | 1994-10-21 | 1999-05-17 | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ335835A (xx) |
-
1999
- 1999-05-17 NZ NZ335835A patent/NZ335835A/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3647895A (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| DE69334266D1 (de) | Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate | |
| ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
| GR3027620T3 (en) | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products | |
| AU2750092A (en) | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid | |
| IL116559A0 (en) | Chimeric proteins | |
| WO1995030435A3 (en) | Compositions and treatment for multiple sclerosis | |
| CA2494338A1 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
| NZ335835A (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| CA2139353A1 (en) | Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder | |
| BG101846A (en) | HUMAN DNase I VARIANTS | |
| EP0342015A3 (en) | Peptides, their use and pharmaceutical compositions containing them | |
| BG101847A (en) | Human dnase i variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |